Tests acetazolamide as an add-on for treatment resistant schizophrenia
Compares acetazolamide with placebo in adults with treatment resistant schizophrenia.
Plain-language title generated from the registry record
Registry title: Acetazolamide for Treatment Resistant Schizophrenia
Key facts
- Where
- Bangalore, IndiaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-55 with schizophrenia that has not responded to treatment. They get acetazolamide or a placebo on top of their usual antipsychotic.
- Age
- 18-55 years
- Sex
- All genders can join.
- Disease stage
- Schizophrenia not helped by earlier treatment, with a PANSS total score above 60 and a score above 4 on one or more of the positive symptom items (P1-P7), after 6 weeks of treatment at therapeutic doses with different antipsychotics on 2 occasions.
- Earlier treatment
- Must have been on a stable dose of an antipsychotic drug for more than 1 month, continued throughout the study. Must not have had acetazolamide before.
Main reasons for not taking part
- Drug or alcohol abuse in the past month, or dependence in the past 6 months (methadone for opiate withdrawal is allowed)
- Medical or neurological illness that may make the course unstable, such as epilepsy
- Pregnancy
- Reasons acetazolamide cannot be used: allergy to it, renal hyperchloremic acidosis, Addison's disease or adrenal failure, chronic closed angle-closure glaucoma
- Intellectual disability as defined in DSM 5
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT04887792, who can take part
Where in India
- St. John's Medical College HospitalBangalore, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vishwajit Nimgaonkar, MD PhD
- Trial code
- NCT04887792
- Record updated
- 7 July 2026
- Original description
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.Read full original descriptionShow less
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Inclusion: Written informed consent; Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose); PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions; Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study; Not participating in another randomized controlled clinical trial (RCT).
Exclusion: Current or prior treatment with ACZ or history of hypersensitivity to ACZ; History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy; Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma; Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal; Pregnancy; Intellectual disability as defined in DSM 5.